메뉴 건너뛰기
International Journal of Radiation Oncology Biology Physics
Volumn 84, Issue 3, 2012, Pages 619-624
Modern outcomes of inflammatory breast cancer
Author keywords

Inflammatory breast cancer; Multimodality treatment; Survival outcomes; Taxane; Trastuzumab
Indexed keywords

BREAST CANCER; MULTI-MODALITY; SURVIVAL OUTCOMES; TAXANE; TRASTUZUMAB;
EID: 84866729242     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2012.01.030     Document Type: Article
Times cited : (45)
References (19)
  • 1
    • 21244466004 scopus 로고    scopus 로고
    • Trends in inflammatory breast carcinoma incidence and survival: The surveillance, epidemiology, and end results program at the National Cancer Institute
    • K.W. Hance, W.F. Anderson, and S.S. Devesa Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute J Natl Cancer Inst 97 2005 966 975
    • (2005) J Natl Cancer Inst , vol.97 , pp. 966-975
    • Hance, K.W.1    Anderson, W.F.2    Devesa, S.S.3
  • 2
    • 3242752900 scopus 로고    scopus 로고
    • Population-based statistics for women diagnosed with inflammatory breast cancer (United States)
    • P.A. Wingo, P.M. Jamison, and J.L. Young Population-based statistics for women diagnosed with inflammatory breast cancer (United States) Cancer Causes Control 15 2004 321 328
    • (2004) Cancer Causes Control , vol.15 , pp. 321-328
    • Wingo, P.A.1    Jamison, P.M.2    Young, J.L.3
  • 3
    • 64249099411 scopus 로고    scopus 로고
    • American Joint Committee on Cancer 7th ed. Springer New York
    • S. Edge American Joint Committee on Cancer AJCC cancer staging manual 7th ed. 2010 Springer New York
    • (2010) AJCC Cancer Staging Manual
    • Edge, S.1
  • 4
    • 0023254122 scopus 로고
    • Inflammatory breast cancer: Determination of prognostic factors by univariate and multivariate analysis
    • B. Chevallier, B. Asselain, and A. Kunlin Inflammatory breast cancer: Determination of prognostic factors by univariate and multivariate analysis Cancer 60 1987 897 902
    • (1987) Cancer , vol.60 , pp. 897-902
    • Chevallier, B.1    Asselain, B.2    Kunlin, A.3
  • 5
    • 0028234643 scopus 로고
    • Management of locally advanced carcinoma of the breast. II. Inflammatory carcinoma
    • C.A. Perez, J.N. Fields, and P.M. Fracasso Management of locally advanced carcinoma of the breast. II. Inflammatory carcinoma Cancer 74 Suppl 1 1994 466 476
    • (1994) Cancer , vol.74 , Issue.SUPPL. 1 , pp. 466-476
    • Perez, C.A.1    Fields, J.N.2    Fracasso, P.M.3
  • 6
    • 0019851296 scopus 로고
    • Inflammatory cancer of the breast: Analysis of 114 cases
    • F. Bozzetti, R. Saccozzi, and M. De Lena Inflammatory cancer of the breast: Analysis of 114 cases J Surg Oncol 18 1981 355 361
    • (1981) J Surg Oncol , vol.18 , pp. 355-361
    • Bozzetti, F.1    Saccozzi, R.2    De Lena, M.3
  • 7
    • 77953554463 scopus 로고    scopus 로고
    • Locoregional outcomes of inflammatory breast cancer patients treated with standard fractionation radiation and daily skin bolus in the taxane era
    • S. Damast, A.Y. Ho, and L. Montgomery Locoregional outcomes of inflammatory breast cancer patients treated with standard fractionation radiation and daily skin bolus in the taxane era Int J Radiat Oncol Biol Phys 77 2010 1105 1112
    • (2010) Int J Radiat Oncol Biol Phys , vol.77 , pp. 1105-1112
    • Damast, S.1    Ho, A.Y.2    Montgomery, L.3
  • 8
    • 51449107581 scopus 로고    scopus 로고
    • Locoregional treatment outcomes after multimodality management of inflammatory breast cancer
    • I.J. Bristol, W.A. Woodward, and E.A. Strom Locoregional treatment outcomes after multimodality management of inflammatory breast cancer Int J Radiat Oncol Biol Phys 72 2008 474 484
    • (2008) Int J Radiat Oncol Biol Phys , vol.72 , pp. 474-484
    • Bristol, I.J.1    Woodward, W.A.2    Strom, E.A.3
  • 9
    • 0242500950 scopus 로고    scopus 로고
    • Ten-year outcome after combined modality therapy for inflammatory breast cancer
    • E.E.R. Harris, D. Schultz, and H. Bertsch Ten-year outcome after combined modality therapy for inflammatory breast cancer Int J Radiat Oncol Biol Phys 55 2003 1200 1208
    • (2003) Int J Radiat Oncol Biol Phys , vol.55 , pp. 1200-1208
    • Harris, E.E.R.1    Schultz, D.2    Bertsch, H.3
  • 10
    • 1242314238 scopus 로고    scopus 로고
    • Inflammatory breast carcinoma: Outcomes with trimodality therapy for nonmetastatic disease
    • S.L. Liauw, R.K. Benda, and C.G. Morris Inflammatory breast carcinoma: Outcomes with trimodality therapy for nonmetastatic disease Cancer 100 2004 920 928
    • (2004) Cancer , vol.100 , pp. 920-928
    • Liauw, S.L.1    Benda, R.K.2    Morris, C.G.3
  • 11
    • 78650608807 scopus 로고    scopus 로고
    • International expert panel on inflammatory breast cancer: Consensus statement for standardized diagnosis and treatment
    • S. Dawood, S.D. Merajver, and P. Viens International expert panel on inflammatory breast cancer: Consensus statement for standardized diagnosis and treatment Ann Oncol 22 2011 515 523
    • (2011) Ann Oncol , vol.22 , pp. 515-523
    • Dawood, S.1    Merajver, S.D.2    Viens, P.3
  • 12
    • 33646376727 scopus 로고    scopus 로고
    • Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer
    • J. Hurley, P. Doliny, and I. Reis Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer J Clin Oncol 24 2006 1831 1838
    • (2006) J Clin Oncol , vol.24 , pp. 1831-1838
    • Hurley, J.1    Doliny, P.2    Reis, I.3
  • 13
    • 0035476303 scopus 로고    scopus 로고
    • Paclitaxel in the multimodality treatment for inflammatory breast carcinoma
    • M. Cristofanilli, A.U. Buzdar, and N. Sneige Paclitaxel in the multimodality treatment for inflammatory breast carcinoma Cancer 92 2001 1775 1782
    • (2001) Cancer , vol.92 , pp. 1775-1782
    • Cristofanilli, M.1    Buzdar, A.U.2    Sneige, N.3
  • 14
    • 1842530208 scopus 로고    scopus 로고
    • Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: The M. D. Anderson Cancer Center experience
    • M. Cristofanilli, A.M. Gonzalez-Angulo, and A.U. Buzdar Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: The M. D. Anderson Cancer Center experience Clin Breast Cancer 4 2004 415 419
    • (2004) Clin Breast Cancer , vol.4 , pp. 415-419
    • Cristofanilli, M.1    Gonzalez-Angulo, A.M.2    Buzdar, A.U.3
  • 15
    • 18644384419 scopus 로고    scopus 로고
    • Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer
    • E. Turpin, I. Bièche, and P. Bertheau Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer Oncogene 21 2002 7593 7597
    • (2002) Oncogene , vol.21 , pp. 7593-7597
    • Turpin, E.1    Bièche, I.2    Bertheau, P.3
  • 16
    • 0033050164 scopus 로고    scopus 로고
    • Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy
    • H.M. Kuerer, L.A. Newman, and T.L. Smith Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy J Clin Oncol 17 1999 460 469
    • (1999) J Clin Oncol , vol.17 , pp. 460-469
    • Kuerer, H.M.1    Newman, L.A.2    Smith, T.L.3
  • 17
    • 39149111633 scopus 로고    scopus 로고
    • Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
    • P. Rastogi, S.J. Anderson, and H.D. Bear Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 J Clin Oncol 26 2008 778 785
    • (2008) J Clin Oncol , vol.26 , pp. 778-785
    • Rastogi, P.1    Anderson, S.J.2    Bear, H.D.3
  • 18
    • 26844503270 scopus 로고    scopus 로고
    • Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
    • M.J. Piccart-Gebhart, M. Procter, and B. Leyland-Jones Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 2005 1659 1672
    • (2005) N Engl J Med , vol.353 , pp. 1659-1672
    • Piccart-Gebhart, M.J.1    Procter, M.2    Leyland-Jones, B.3
  • 19
    • 26844536978 scopus 로고    scopus 로고
    • Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    • E.H. Romond, E.A. Perez, and J. Bryant Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 2005 1673 1684
    • (2005) N Engl J Med , vol.353 , pp. 1673-1684
    • Romond, E.H.1    Perez, E.A.2    Bryant, J.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.